GSK2656157

1337532-29-2

C23H21FN6O

DMSO : >= 41 mg/mL (98.45 mM)

Cell Cycle/DNA Damage; Autophagy

GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC₅₀ value of 0.9 nM, and highly selective for PERK with IC₅₀ values of > 100 nM against a panel of 300 kinases. IC50 & Target: IC50: 0.9 nM (PERK) In Vitro: GSK2656157 results in inhibition of PERK activation as well as decreases in the downstream substrates, phospho-eIF2alpha, ATF4, and CHOP with an IC₅₀ in the range of 10-30 nM in the BxPC3 pancreatic tumor cell line. Cells that are exposed to 1 uM GSK2656157 before UPR induction are able to block this effect on de novo protein synthesis^[1]. GSK2656157 causes the activation of another eIF2alpha kinase to compensate for the loss of PERK activity in HT1080 cells. GSK2656157 inhibits the growth of the HT1080 cells^[2]. GSK2656157 inhibits LPS-induced IL-1beta production, LPS-induced Caspase 1 activation and LPS-induced eIF-2alpha phosphorylation, but does not inhibit LPS-induced TNF-alpha production^[3]. In Vivo: GSK2656157 (1.5-150 mg/kg, p.o.) results in dose-dependent inhibition of phospho-PERK Thr980, with more than 80% inhibition at 50 and 150 mg/kg. GSK2656157 (50-150 mg/kg, p.o.) results in dose-dependent inhibition of tumor growth in human tumor xenograft models^[1].